{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:11:48Z","timestamp":1746191508691},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ejphar.2015.08.059","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T22:32:55Z","timestamp":1441233175000},"page":"332-336","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Drug\u2013drug interactions between clopidogrel and novel cardiovascular drugs"],"prefix":"10.1016","volume":"765","author":[{"given":"Francesco","family":"Pelliccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.08.059_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jacc.2007.04.041","article-title":"Clopidogrel\u2013statin interaction: myth or reality?","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib2","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/eurheartj\/ehq494","article-title":"A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3 trial","volume":"32","author":"Angiolillo","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2015.08.059_bib5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel\u2013drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J. Am. Coll. Cardiol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2015.08.059_bib6","first-page":"S6","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2015.08.059_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","volume":"52","author":"Bhatt","year":"2008","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.ejphar.2015.08.059_bib8","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib9","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2015.08.059_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2015.08.059_bib11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-014-1710-1","article-title":"Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: results of the randomized DOSAPI study","volume":"70","author":"Collet","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.110.957829","article-title":"Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study","volume":"3","author":"Ferreiro","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ejphar.2015.08.059_bib13","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2015.08.059_bib14","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","article-title":"A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers","volume":"59","author":"Frelinger","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1616220","article-title":"ADP receptors of platelets and their inhibition","volume":"86","author":"Gachet","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2015.08.059_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2015.08.059_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/CIRCINTERVENTIONS.111.963405","article-title":"Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"5","author":"Good","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ejphar.2015.08.059_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/hrt.2009.171488","article-title":"Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition","volume":"96","author":"Gremmel","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2015.08.059_bib20","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH09-08-0516","article-title":"The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response","volume":"103","author":"Harmsze","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2015.08.059_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3810\/pgm.2014.05.2772","article-title":"Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling","volume":"126","author":"Johnson","year":"2014","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejphar.2015.08.059_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.thromres.2013.04.031","article-title":"Pathways of platelet activation and unexplained clopidogel variability: causes of poor response to clopidogrel","volume":"132","author":"Kounis","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2015.08.059_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2015.08.059_bib25","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the, Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/heartjnl-2012-302801","article-title":"Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial","volume":"99","author":"Li","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2015.08.059_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2796.2009.02119.x","article-title":"Influence of statin treatment on platelet inhibition by clopidogrel-a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment","volume":"266","author":"Malmstr\u00f6m","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.08.059_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.thromres.2011.06.029","article-title":"Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole","volume":"128","author":"Moceri","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2015.08.059_bib29","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib30","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2015.08.059_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/clp.10.28","article-title":"Pitavastatin: a distinctive lipid lowering drug","volume":"5","author":"Ose","year":"2010","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib32","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1093\/eurheartj\/ehs083","article-title":"Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCELSTATIN) study","volume":"33","author":"Park","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11239-015-1203-9","volume":"40","author":"Pelliccia","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ejphar.2015.08.059_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejphar.2014.01.006","article-title":"Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy \u2013 the PEARL randomized cross-over study","volume":"725","author":"Pelliccia","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1253\/circj.CJ-13-1216","article-title":"Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy","volume":"78","author":"Pelliccia","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jacc.2011.06.031","article-title":"Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study","volume":"58","author":"Pham","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1160\/TH03-12-0738","article-title":"ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin","volume":"92","author":"Piorkowski","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2015.08.059_bib38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ahj.2010.11.010","article-title":"Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting","volume":"161","author":"Sarafoff","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2125.2012.04169.x","article-title":"Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation","volume":"74","author":"Schmidt","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH06-08-0420","article-title":"Thienopyridines in cardiovascular disease: focus on clopidogrel resistance","volume":"97","author":"Siller-Matula","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2015.08.059_bib41","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.08.059_bib43","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/heartjnl-2013-304498","article-title":"2012 ESC STEMI guidelines and reperfusion therapy: evidence-based recommendations, ensuring optimal patient management","volume":"99","author":"Steg","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2015.08.059_bib44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ahj.2006.01.001","article-title":"Clopidogrel\u2013statin interaction: a mountain or a mole hill?","volume":"152","author":"Steinhubl","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2015.08.059_bib45","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2015.08.059_bib46","first-page":"457","article-title":"The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease","volume":"266","author":"Vinholt","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2015.08.059_bib47","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.08.059_bib48","first-page":"449","article-title":"Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy","volume":"11","author":"Wang","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejphar.2015.08.059_bib49","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T09:47:13Z","timestamp":1582537633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915302314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":49,"alternative-id":["S0014299915302314"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.059","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug\u2013drug interactions between clopidogrel and novel cardiovascular drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}